MARKET

COLL

COLL

Collegium Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.06
+0.78
+3.85%
After Hours: 21.06 0 0.00% 16:08 12/06 EST
OPEN
20.52
PREV CLOSE
20.28
HIGH
21.20
LOW
20.25
VOLUME
251.11K
TURNOVER
--
52 WEEK HIGH
22.28
52 WEEK LOW
10.01
MARKET CAP
706.08M
P/E (TTM)
-62.1422
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of COLL and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

COLL News

  • Hedge Funds Love Unisys Corporation (UIS) Way More Than These 4 Stocks
  • Insider Monkey.7h ago
  • Market Is Turning A Blind Eye To Collegium's Lack Of Debt And Opioid Lawsuits
  • Seeking Alpha - Article.3d ago
  • The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial
  • Benzinga.3d ago
  • The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen
  • Benzinga.11/27 12:26

More

Industry

Pharmaceuticals
+0.53%
Pharmaceuticals & Medical Research
+0.68%

Hot Stocks

Name
Price
%Change

About COLL

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
More

Webull offers Collegium Pharmaceutical Inc (COLL) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.